文献速递血栓与止血

丹麦内脏静脉血栓患者出血与动脉心血管事件风险:一项基于人群的队列研究

Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study.
PubMed 文献 · Lancet Haematol · 2018-09-07

该研究基于丹麦全国登记数据,纳入1994年1月1日至2013年11月30日诊断的1915例内脏静脉血栓患者,并与18373例深静脉血栓或肺栓塞患者及19150名一般人群按性别、年龄和诊断年份匹配比较。结果显示内脏静脉血栓患者诊断后30天内出血绝对风险为4.3%,调整后出血风险显著高于深静脉血栓或肺栓塞患者(HR 9.64)和一般人群(HR 39.79);动脉心血管事件风险在诊断后1年内也显著升高。作者认为医生应认识这些风险。

要点

  • 内脏静脉血栓患者诊断后30天内出血绝对风险为4.3%(95%CI 3.5-5.3)。
  • 与深静脉血栓或肺栓塞患者相比,30天内出血调整HR为9.64(95%CI 6.46-14.40)。
  • 诊断后1年内动脉心血管事件绝对风险为7.0%(95%CI 5.8-8.4)。

核心结论

  • 与深静脉血栓或肺栓塞患者及一般人群相比,内脏静脉血栓患者在诊断后多年内出血和动脉心血管事件风险增加。
  • 作者认为医生应认识内脏静脉血栓患者的这些风险。

研究设计与样本

  • 基于丹麦国家患者登记系统(DNPR)的基于人群的队列研究。
  • 纳入1994年1月1日至2013年11月30日诊断的内脏静脉血栓患者1915例,累计源人群7 310 450人。
  • 比较队列为同期深静脉血栓或肺栓塞患者18373例及一般人群19150人,按性别、年龄和诊断年份匹配,每例内脏静脉血栓患者匹配10名对照。
  • 计算绝对风险并使用比例风险回归计算调整后的风险比(HR)。

主要发现

  • 内脏静脉血栓患者中位随访1年(IQR 0.1-3.9)。
  • 诊断后30天内出血绝对风险为4.3%(95%CI 3.5-5.3),调整后出血风险与深静脉血栓或肺栓塞患者相比HR为9.64(95%CI 6.46-14.40),与一般人群相比HR为39.79(95%CI 19.44-81.46)。
  • 诊断后1年内出血风险仍显著升高,与深静脉血栓或肺栓塞患者相比HR为3.01(95%CI 2.28-3.97),与一般人群相比HR为6.83(95%CI 4.83-9.65)。
  • 与深静脉血栓或肺栓塞患者相比,出血风险升高持续至10年(HR 1.93,95%CI 1.12-3.34);与一般人群相比持续至19年(HR 5.90,95%CI 2.22-15.64)。
  • 动脉心血管事件风险在诊断后30天内绝对风险为3.3%(95%CI 2.6-4.2),31-365天为7.0%(95%CI 5.8-8.4);调整后与深静脉血栓或肺栓塞患者相比30天内HR为7.05(95%CI 4.74-10.48),31-365天HR为2.10(95%CI 1.62-2.72);与一般人群相比分别为15.75(95%CI 9.26-26.79)和3.17(95%CI 2.34-4.27)。

临床怎么用

  • 作者认为医生应认识内脏静脉血栓患者出血和动脉心血管事件的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about adverse events following splanchnic vein thrombosis. Venous thromboembolism has been associated with increased risks of bleeding and arterial cardiovascular events. To learn more about the clinical course of splanchnic vein thrombosis, we examined the risks of bleeding and arterial cardiovascular events in patients with the disease, and compared them with the risks in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and individuals from the general population. METHODS: In this population-based cohort study, we used data for all patients with a diagnosis of splanchnic vein thrombosis recorded in the Danish National Patient Registry (DNPR) between Jan 1, 1994, and Nov 30, 2013 (cumulative source population 7 310 450 individuals). We created two comparison cohorts using data from the DNPR and the Civil Registration System for the same period: one of patients with DVT or PE and another of individuals from the general population. Comparison cohorts (ten comparators per patient with splanchnic vein thrombosis) were matched on sex, age, and calendar year of diagnosis. We calculated absolute risks and used proportional hazard regression to calculate adjusted hazard ratios (HRs) for the primary outcomes of bleeding and arterial cardiovascular events after splanchnic vein thrombosis diagnosis (or the index date for comparison cohorts). FINDINGS: 1915 patients with splanchnic vein thrombosis, 18 373 patients with DVT or PE, and 19 150 individuals from the general population were included in the study. Patients with splanchnic vein thrombosis were followed up for a median of 1 year (IQR 0·1-3·9). These patients had a high risk of bleeding in the 30 days after diagnosis, both in absolute terms (4·3% [95% CI 3·5-5·3]) and in adjusted models (HR 9·64 [95% CI 6·46-14·40] vs DVT or PE; 39·79 [19·44-81·46] vs general population). Bleeding risk was still significantly increased in patients with splanchnic vein thrombosis up to 1 year after diagnosis (HR 3·01 [95% CI 2·28-3·97] vs DVT or PE; 6·83 [4·83-9·65] vs general population), and remained elevated for up to 10 years compared with patients with DVT or PE (1·93 [1·12-3·34]) and for up to 19 years compared with the general population (5·90 [2·22-15·64]). The risk of arterial cardiovascular events in patients with splanchnic vein thrombosis was high in the year after diagnosis (absolute risk 3·3% [95% CI 2·6-4·2] up to 30 days; 7·0% [5·8-8·4] up to 31-365 days), and in adjusted models was significantly higher than in patients with DVT or PE (HR 7·05 [95% CI 4·74-10·48] up to 30 days; 2·10 [1·62-2·72] up to 31-365 days) and individuals from the general population (15·75 [9·26-26·79] and 3·17 [2·34-4·27], respectively). However, this risk did not remain significantly elevated above that of patients with DVT or PE after 1 year or the general population after 5 years. INTERPRETATION: Patients with splanchnic vein thrombosis are at increased risk of adverse outcomes, particularly bleeding but also arterial cardiovascular events, for years after diagnosis compared with patients with DVT or PE and the general population. Physicians should be cognisant of these risks in patients with splanchnic vein thrombosis. FUNDING: The Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck Foundation and the Novo Nordisk Foundation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Søgaard KK, Adelborg K, Darvalics B, et al. Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. Lancet Haematol. 2018. PMID: 30201587. doi:10.1016/S2352-3026(18)30133-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。